Aug 05, 2019
Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer
Apr 16, 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Apr 03, 2019
Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta
Mar 25, 2019
Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer
Feb 27, 2019
Aprea Therapeutics Adds New Investor to Series C Financing
Dec 02, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego
Nov 30, 2018
Aprea Therapeutics Closes EUR 50 Million Financing
Jun 17, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm
Apr 16, 2018
Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago
Jan 04, 2018
Aprea Therapeutics Announces Presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco
Aug 02, 2017
Aprea Therapeutics Announces First Patient Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Platinum-Resistant High-Grade Serous Ovarian Cancer